BridgeMD
SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high- intermediate risk endometrial cancer: a proof-of-concept study
EU CTIS ID: 2024-516708-40-00
What this study is testing
to evaluate feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with stage I-II high/high-intermediate risk endometrial cancer
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Clinical FIGO 2012 stage I-II high/high-intermediate risk endometrial cancer; - Scheduled for robot-assisted full pelvic and para-aortic staging; - Age ≥18 years and able to provide informed consent.
You likely can't join if
- - Pregnancy or current breastfeeding (in women at a ferile age with a possibility of prenancy, confirmation by a pregnancy test is current standard of care); - Prior severe allergic reaction to iodine; - Severe renal insufficiency (stage 3 or 4); - Clinical or radiological evidence of metastatic disease.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.